Inherited Cancer Syndromes and the DNA Damage Response

Size: px
Start display at page:

Download "Inherited Cancer Syndromes and the DNA Damage Response"

Transcription

1 Inherited Cancer Syndromes and the DNA Damage Response

2 Inherited Breast Cancer and DNA Double- Strand Break Repair Michal Goldberg Department of GeneGcs The Hebrew University Cancer Hub, March 2014

3 Hallmarks of cancer cells MutaGon accumulagon Chromosomal instability Changes in the structure and number of chromosomes Hanahan and Weinberg. Cell, 2011

4 Hallmarks of cancer cells Hanahan and Weinberg. Cell, 2011

5 DNA damage and DNA repair Damaging agents (internal and external) X- rays Oxygen radicals AlkylaGng agents X DDR UV light AromaGc compounds X- ray RadiomimeGc drugs ReplicaGon errors Collapse of the replicagon fork The DNA damage response Uracil Abasic site 8- Oxoguanine Single- strand break Genomic instability Bulky adduct Thymidine dimers Checkpoint DNA Apoptosis / acgvagon Base- excision repair NucleoGde- excision Senescence repair (BER) repair (NER) Interstrand cross- link Double- strand break Homologous recombinagon Non- homologous end joining Mismatch Inser;on/dele;on Double- strand break Mismatch repair Negri5o. Nature Educa;on 3(9):26

6 DNA damage and DNA repair Damaging agents (internal and external) X- rays Oxygen radicals AlkylaGng agents DDR UV light AromaGc compounds X- ray RadiomimeGc drugs ReplicaGon errors Collapse of the replicagon fork The DNA damage response Uracil Abasic site 8- Oxoguanine Single- strand break Bulky adduct Thymidine dimers Interstrand cross- link Double- strand break Mismatch Inser;on/dele;on Double- strand break Checkpoint DNA Apoptosis / acgvagon Base- excision repair NucleoGde- excision Senescence repair (BER) repair (NER) Homologous recombinagon Non- homologous end joining Mismatch repair Negri5o. Nature Educa;on 3(9):26

7 DNA damage and DNA repair Damaging agents (internal and external) X- rays Oxygen radicals AlkylaGng agents DDR UV light AromaGc compounds X- ray RadiomimeGc drugs ReplicaGon errors Collapse of the replicagon fork The DNA damage response Uracil Abasic site 8- Oxoguanine Single- strand break Bulky adduct Thymidine dimers Interstrand cross- link Double- strand break Mismatch Inser;on/dele;on Double- strand break Checkpoint DNA Apoptosis / acgvagon Base- excision repair NucleoGde- excision Senescence repair (BER) repair (NER) Homologous recombinagon Non- homologous end joining Mismatch repair Negri5o. Nature Educa;on 3(9):26

8 DNA double- strand break (DSB) repair Resec;on of the 5ʹ strands to generate 3ʹ single- stranded DNA HR Homologous recombinagon ; NHEJ Non- homologous end joining ; SSA Single- strand annealing ; BIR break- induced replicagon ; DSBR HR repair ; SDSA Synthesis- dependent strand- annealing Aguilera & Gómez- González, Nat. Rev. Genet (2008)

9 DSB repair and genomic instability Aguilera & Gómez- González, Nat. Rev. Genet (2008)

10 DSB repair and genomic instability Repair impairment Aguilera & Gómez- González, Nat. Rev. Genet (2008)

11 Familial Breast Cancer and DNA DSB Repair

12 Breast cancer suscepgbility genes Apostolou & Fos;ra. Biomed Res Int. (2013)

13 HR repair genes and inherited breast cancer Aguilera & Gómez- González, Nat. Rev. Genet (2008)

14 HR repair genes and inherited breast cancer Zhang & Powell. Mol Cancer Res. (2005) Adapted from: Mladenov et al. Fornt Oncol (2013)

15 Screen for DDR genes involved in estrogen- dependent cancers Genes that are upregulated by estrogen Genes that have a role in the DNA damage response SelecGon for driver mutagons in breast and ovarian cancers Strauss et al. Unpublished Carmit Strauss

16 HR repair genes and inherited breast cancer # Zhang & Powell. Mol Cancer Res. (2005) # Strauss et al. Unpublished BRCA2 = FANCD1 PALB2 = FANCN Adapted from: Mladenov et al. Fornt Oncol (2013)

17 Genes predisposing to breast cancer are mutated in fanconi anemia ICL (interstrand crosslinks) BACH1 = BRIP1 = FANCJ Branzei & Foiani. Nat Rev Mol Cell Biol. (2010)

18 HR repair genes and inherited breast cancer why breast cancer??? Mladenov et al. Fornt Oncol (2013)

19 Estrogen acgvity Droog et al., Eur J Pharmacol. 2013

20 Estrogen- induced DNA repair genes Adapted from: Mladenov et al. Fornt Oncol (2013)

21 Screen for DDR genes involved in estrogen- dependent cancers Genes that are upregulated by estrogen Genes that have a role in the DNA damage response SelecGon for driver mutagons in breast and ovarian cancers Strauss et al. Unpublished Carmit Strauss

22 Estrogen- induced DNA repair genes # # # # # # # Strauss et al. Unpublished Adapted from: Mladenov et al. Fornt Oncol (2013)

23 Estrogen induces DSBs at promoters of estrogen- induced genes Williamson & Lees- Miller. Carcinogenesis (2011)

24 Genomic instability due to DSBs at estrogen- responding genes Inherited mutagon in HR repair gene, regulated by estrogen HR repair gene, regulated by estrogen

25 Genomic instability due to DSBs at estrogen- responding genes Estrogen

26 Genomic instability due to DSBs at estrogen- responding genes Estrogen

27 DNA repair genes and cancer Adapted from: Berger et al., Nature (2011)

28 DNA double- strand break (DSB) repair Aguilera & Gómez- González, Nat. Rev. Genet (2008)

29 Genomic instability due to DSBs at estrogen- responding genes DSB repair Terminal delegon MitoGc recombinagon Small insergon/ delegon or a point mutagon Gene conversion TranslocaGon

30 DNA repair genes and cancer Adapted from: Berger et al., Nature (2011)

31 Genomic instability due to DSBs at estrogen- responding genes DSB repair Terminal delegon Small insergon/ delegon or a point mutagon TranslocaGon

32 HR repair genes and cancer HR repair gene B HR repair gene C Adapted from: Berger et al., Nature (2011)

33 A model: HR repair genes and estrogen- dependent cancers Promotes proliferagon Estrogen Upregulates HR repair gene expression Inherited mutagon (heterozygous) in HR repair gene Genomic instability Estrogen DSB formagon at promoters of E2- upregulated genes

34 HR repair genes and inherited breast cancer Treatment # # Strauss et al. Unpublished Adapted from: Mladenov et al. Fornt Oncol (2013)

35 Single- strand break repair and poly (ADP- ribose) polymerase (PARP) Adapted from: Itamochi, World Biol Chem (2010)

36 Single- strand break repair and poly (ADP- ribose) polymerase (PARP) Adapted from: Itamochi, World Biol Chem (2010)

37 PARP inhibitors Cur;n, Biochem Soc Trans (2014)

38 PARP inhibitors Chen et al, Arch Gynecol Obstet (2013) IV intravenous PO - oral

39 Single- strand break repair and poly (ADP- ribose) polymerase (PARP) PARPi resistance Adapted from: Itamochi, World Biol Chem (2010)

40

41

Inhibidores de PARP Una realidad? dónde y cuando?

Inhibidores de PARP Una realidad? dónde y cuando? Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed

More information

Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology

Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No

More information

DNA/RNA: polynucleotide chains

DNA/RNA: polynucleotide chains What is DNA? DNA/RNA: polynucleotide chains Phosphate Base Sugar (2 OH=ribose, 2 H=deoxyribose) Nucleotide =sugar+phosphate+base DNA is a double helix DNA damage and repair How is DNA damaged? How is DNA

More information

PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future.

PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. Dr.ssa Angela Toss Centro Oncologico Modenese Università di Modena e Reggio Emilia MECHANISMS OF

More information

Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2

Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Introduction Most commonly diagnosed cancer in South African women and the second most commonly diagnosed cancer in Black women

More information

DNA repair and synthetic lethality

DNA repair and synthetic lethality Washington University School of Medicine Digital Commons@Becker Open Access Publications 2011 DNA repair and synthetic lethality Gong-she Guo Shandong University Feng-mei Zhang Shandong University Rui-jie

More information

Biochemistry 201: DNA repair January 24, 26, 2000 Gilbert Chu

Biochemistry 201: DNA repair January 24, 26, 2000 Gilbert Chu 1) Why study DNA repair? Biochemistry 201: DNA repair January 24, 26, 2000 Gilbert Chu The genome is assaulted by a myriad of different agents that cause DNA damage. Sources of damage can be both exogenous

More information

PARP inhibitors for breast cancer

PARP inhibitors for breast cancer PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases

More information

Targeting DNA base excision repair: a new strategy for personalised cancer therapy

Targeting DNA base excision repair: a new strategy for personalised cancer therapy GOULSTONIAN LECTURE Clinical Medicine 2012, Vol 12, No 6: s42 s46 Targeting DNA base excision repair: a new strategy for personalised cancer therapy Rachel Abbotts and Srinivasan Madhusudan Introduction

More information

Drugging the Cancers Addicted to DNA Repair

Drugging the Cancers Addicted to DNA Repair JNCI J Natl Cancer Inst (2017) 109(11): djx059 doi: 10.1093/jnci/djx059 First published online May 18, 2017 Review Drugging the Cancers Addicted to DNA Repair Jac A. Nickoloff, Dennie Jones, Suk-Hee Lee,

More information

The Need for a PARP in vivo Pharmacodynamic Assay

The Need for a PARP in vivo Pharmacodynamic Assay The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D. Chief Scientific Officer Trevigen, Inc. Gaithersburg, MD Poly(ADP-ribose) polymerases are promising therapeutic targets. In response

More information

Targeting the ATR Kinase in Cancer Therapy

Targeting the ATR Kinase in Cancer Therapy Targeting the ATR Kinase in Cancer Therapy 2017 Chabner Colloquium October 30, 2017 Lee Zou MGH Cancer Center Harvard Medical School Disclosure Consultant/advisory role: Loxo Oncology DNA Damage and Replication

More information

Mutagenesis. David M. DeMarini, Ph.D. University of North Carolina at Chapel Hill.

Mutagenesis. David M. DeMarini, Ph.D. University of North Carolina at Chapel Hill. Mutagenesis David M. DeMarini, Ph.D. University of North Carolina at Chapel Hill ddemarini@nc.rr.com 1. DNA as the Target Mutagenesis Overview 2. DNA Damage (The Mutagenesis Paradigm) A. Types of Damage

More information

Prognostic value of DNA repair based stratification of hepatocellular carcinoma

Prognostic value of DNA repair based stratification of hepatocellular carcinoma Prognostic value of DNA repair based stratification of hepatocellular carcinoma Zhuo Lin 1, 2 #, Shi-Hao Xu 3 #, Hai-Qing Wang 4, Yi-Jing Cai 1, 2, Li Ying 3, Mei Song 1, 2, Yu-Qun Wang 1, 2, Shan-Jie

More information

Virtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies

Virtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet

More information

Chapter 9. Cells Grow and Reproduce

Chapter 9. Cells Grow and Reproduce Chapter 9 Cells Grow and Reproduce DNA Replication DNA polymerase Addition of a nucleotide to the 3 end of a growing strand Use dntps as substrate Release of pyrophosphate Initiation of Replication Replication

More information

Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy

More information

Variants in DNA Repair Genes and Glioblastoma. Roberta McKean-Cowdin, PhD

Variants in DNA Repair Genes and Glioblastoma. Roberta McKean-Cowdin, PhD Variants in DNA Repair Genes and Glioblastoma Advances in Bioinformatics and Genomics Symposium February 19, 2010 Roberta McKean-Cowdin, PhD Department of Preventive Medicine, University of Southern California

More information

Genomic instability. Amin Mahpour

Genomic instability. Amin Mahpour Genomic instability Amin Mahpour 1 Some questions to ponder What is Genomic instability? What factors contribute to the genomic integrity? How we identify these aberrations? 2 PART I: MOLECULAR BIOLOGY

More information

Repair of Broken Chromosomes and Maintenance of Chromosome Stability

Repair of Broken Chromosomes and Maintenance of Chromosome Stability Repair of Broken Chromosomes and Maintenance of Chromosome Stability Jim Haber Brandeis University Genome instability in tumor cells Truncations Translocations Inversions Duplications Amplifications Deletions

More information

University of Groningen

University of Groningen University of Groningen Therapeutic targeting and patient selection for cancers with homologous recombination defects Talens, Francien; Jalving, Mathilde; Gietema, Jourik A.; van Vlugt, Marcel A. T. M.

More information

"BRCAness," PARP and the Triple-Negative Phenotype

BRCAness, PARP and the Triple-Negative Phenotype "BRCAness," PARP and the Triple-Negative Phenotype Prof Alan Ashworth, FRS Disclosures for Professor Alan Ashworth, FRS Consulting Agreements GlaxoSmithKline, Pfizer Inc Patent AstraZeneca Pharmaceuticals

More information

DNA damage and DNA repair

DNA damage and DNA repair DNA damage and DNA repair Susan P. Lees-Miller, PhD, Professor, Departments of Biochemistry & Molecular Biology and Oncology, Southern Alberta Cancer Research Institute, University of Calgary, Calgary,

More information

Importanza del test genetico nel carcinoma mammario ed ovarico

Importanza del test genetico nel carcinoma mammario ed ovarico Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range

More information

BRCA1, a complex protein involved in the maintenance of genomic stability

BRCA1, a complex protein involved in the maintenance of genomic stability STATE-OF-THE-ART REVIEW BRCA1, a complex protein involved in the maintenance of genomic stability Kienan I. Savage and D. Paul Harkin Centre for Cancer Research and Cell Biology, Queen s University Belfast,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)

More information

Review Article DNA Damage as a Driver for Growth Delay: Chromosome Instability Syndromes with Intrauterine Growth Retardation

Review Article DNA Damage as a Driver for Growth Delay: Chromosome Instability Syndromes with Intrauterine Growth Retardation Hindawi BioMed Research International Volume 2017, Article ID 8193892, 14 pages https://doi.org/10.1155/2017/8193892 Review Article DNA Damage as a Driver for Growth Delay: Chromosome Instability Syndromes

More information

Mugimane Manjanatha, Ph.D

Mugimane Manjanatha, Ph.D Genotoxicity of Doxorubicin in F344 Rats by Combining the Comet Assay, Peripheral Blood Micronucleus Test, and Pathway-Focused Gene Expression Profiling Mugimane Manjanatha, Ph.D FDA/NCTR/DGMT DISCLAIMER

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0484 TITLE: PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING ORGANIZATION: University of Washington REPORT DATE: 2014 TYPE OF REPORT: Annual Report PREPARED FOR: U.S. Army

More information

Overview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña

Overview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing

More information

TOUR REPORT. Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad

TOUR REPORT. Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad TOUR REPORT Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad 1. Name and Designation of ICMR IF : Dr. A. Venkateshwari, Assistant Professor 2. Address: Dr.

More information

AllinaHealthSystems 1

AllinaHealthSystems 1 Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective

More information

Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD

Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies

More information

MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS. (Start your clickers)

MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS. (Start your clickers) MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS (Start your clickers) How do mutations arise? And how do they affect a cell and its organism? Mutations: heritable changes in genes Mutations occur in DNA But

More information

Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer

Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health

More information

Cancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?

Cancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in

More information

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2 For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?

More information

Precision Genetic Testing in Cancer Treatment and Prognosis

Precision Genetic Testing in Cancer Treatment and Prognosis Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient

More information

Introduction to Cancer Biology

Introduction to Cancer Biology Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.

More information

Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania

Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic

More information

Ex vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent

Ex vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent Ex vivo functional assays for Homologous Recombination deficiency in breast cancer Dik C. van Gent Breast cancer types treatments ER/PR: anti-hormonal therapy HER2: Herceptin Triple negative (TNBC): no

More information

Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman

Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background

More information

Carrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman

Carrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background

More information

Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease

Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified

More information

Personalised Medicine in Practice. Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil

Personalised Medicine in Practice. Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil Personalised Medicine in Practice Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil Personalised Medicine in Cancer Care Personalised Medicine in Cancer Care

More information

Dissection of breast cancer development and therapy resistance in mouse models. Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

Dissection of breast cancer development and therapy resistance in mouse models. Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands Dissection of breast cancer development and therapy resistance in mouse models Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands GEMMs of human cancer Genetically engineered mouse models

More information

Targeted therapy & Tumor molecular profile. Anton Tikhonov V Bioinformatics Summer School, 2017

Targeted therapy & Tumor molecular profile. Anton Tikhonov V Bioinformatics Summer School, 2017 Targeted therapy & Tumor molecular profile Anton Tikhonov V Bioinformatics Summer School, 2017 What exactly is targeted therapy? It has target It was rationally designed Its target was discovered before

More information

Lynparza. Lynparza (olaparib) Description

Lynparza. Lynparza (olaparib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)

More information

Biology Response Controversies and Advances

Biology Response Controversies and Advances Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER

More information

Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015

Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed

More information

Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects

Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects Int. J. Mol. Sci. 2013, 14, 640-673; doi:10.3390/ijms14010640 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Ovarian Cancer: In Search of Better

More information

Poly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer

Poly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer Showa Univ J Med Sci 25 2, 83 91, June 2013 Original Poly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer Genki TSUKUDA 1 2, Yuko DATE 1, Kunio ASONUMA

More information

Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.

Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action. 1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors

More information

Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment

Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment DOI 10.1186/s12967-016-1027-1 Journal of Translational Medicine REVIEW Open Access Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment Anselmo Papa 1*, Davide Caruso 1, Martina

More information

Update on PARP inhibitors: opportunities and challenges in cancer therapy

Update on PARP inhibitors: opportunities and challenges in cancer therapy Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it

More information

Next Generation DDR Therapeutics

Next Generation DDR Therapeutics Next Generation DDR Therapeutics Q3 2018 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects

More information

6.3 DNA Mutations. SBI4U Ms. Ho-Lau

6.3 DNA Mutations. SBI4U Ms. Ho-Lau 6.3 DNA Mutations SBI4U Ms. Ho-Lau DNA Mutations Gene expression can be affected by errors that occur during DNA replication. Some errors are repaired, but others can become mutations (changes in the nucleotide

More information

Breast & Colon Cancer: Molecular Alterations & Therapeutic Targets Part 1

Breast & Colon Cancer: Molecular Alterations & Therapeutic Targets Part 1 Breast & Colon Cancer: Molecular Alterations & Therapeutic Targets Part 1 Nancy Hynes FMI June 1, 2007 Molecular targets for cancer therapy In the past 25 yrs cancer research has generated a large body

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our

More information

Hide-then-hit to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility to cancer

Hide-then-hit to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility to cancer doi:10.1093/jmcb/mjq054 Journal of Molecular Cell Biology (2011), 3, 59 65 59 Review Hide-then-hit to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility

More information

Germline Testing for Hereditary Cancer with Multigene Panel

Germline Testing for Hereditary Cancer with Multigene Panel Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with

More information

Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático

Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth

More information

PARP AND PROSTATE CANCER

PARP AND PROSTATE CANCER PARP AND PROSTATE CANCER Terrence P McGarty White Paper No 143 February 2017 DNA breaks often lead to Cancer. Double strand breaks are handled by BRCA gene products and Single strand breaks by PARP products.

More information

Recrui ng now. Could you help by joining this study?

Recrui ng now. Could you help by joining this study? Pancrea c cancer POLO study Recrui ng now AstraZeneca is looking for people with BRCA-mutated metasta c pancrea c cancer to join POLO, a clinical study to help scien sts find be er treatments for this disease

More information

DNA Damage Response Genes and the Development of Cancer Metastasis

DNA Damage Response Genes and the Development of Cancer Metastasis DNA Damage Response Genes and the Development of Cancer Metastasis Authors: Constantinos G. Broustas, and Howard B. Lieberman Source: Radiation Research, 181(2) : 111-130 Published By: Radiation Research

More information

Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer

Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer H. Yang, G. Li and W.F. Li Departments of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical

More information

Lynparza. Lynparza (olaparib) Description

Lynparza. Lynparza (olaparib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza

More information

MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS

MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS How do different alleles arise? ( allele : form of a gene; specific base sequence at a site on DNA) Mutations: heritable changes in genes Mutations occur in DNA

More information

Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway

Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway Cell. Mol. Life Sci. (2016) 73:3097 3114 DOI 10.1007/s00018-016-2218-x Cellular and Molecular Life Sciences REVIEW Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway David Lopez-Martinez

More information

GENE EXPRESSION. Amoeba Sisters video 3pk9YVo. Individuality & Mutations

GENE EXPRESSION. Amoeba Sisters video   3pk9YVo. Individuality & Mutations Amoeba Sisters video https://www.youtube.com/watch?v=giez 3pk9YVo GENE EXPRESSION Individuality & Mutations Complete video handout http://www.amoebasisters.com/uploads/ 2/1/9/0/21902384/video_recap_of_muta

More information

DNA double-strand break repair of parental chromatin in ooplasm and origin of de novo mutations. Peter de Boer

DNA double-strand break repair of parental chromatin in ooplasm and origin of de novo mutations. Peter de Boer DNA double-strand break repair of parental chromatin in ooplasm and origin of de novo mutations Peter de Boer Department of Obst.& Gynaecology, Div. Reproductive Medicine Radboud University Nijmegen Medical

More information

Surveying the Human Genome for Genetic Markers Associated with the Mutator Phenotype and Chromosomal Instability. Timothy Lee

Surveying the Human Genome for Genetic Markers Associated with the Mutator Phenotype and Chromosomal Instability. Timothy Lee Surveying the Human Genome for Genetic Markers Associated with the Mutator Phenotype and Chromosomal Instability by Timothy Lee A thesis submitted in conformity with the requirements for the degree of

More information

The lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):

The lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24): DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence

More information

Learning Objectives. Page 1

Learning Objectives. Page 1 Learning Objectives 1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation. 2. Explore recent advances in

More information

XRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis

XRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis ONCOLOGY LETTERS 9: 2425-2429, 2015 XRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis JINGHUA FAN 1, YUHUA FAN 2, XIAOXIAO KANG 1 and LIMIN ZHAO 1 1 Department of Dermatology, Xi'an

More information

PRINCIPAL INVESTIGATOR: Robert L. Nussbaum, MD. CONTRACTING ORGANIZATION: University of California San Francisco San Francisco, CA 94103

PRINCIPAL INVESTIGATOR: Robert L. Nussbaum, MD. CONTRACTING ORGANIZATION: University of California San Francisco San Francisco, CA 94103 Award Number: W81XWH-12-1-0569 TITLE: Functional Analysis of Variants of Unknown Significance in BRCA1 and BRCA2 Using Complementation of a Synthetic Lethal Interaction with PARP Inhibition PRINCIPAL INVESTIGATOR:

More information

Update on PARP inhibitors

Update on PARP inhibitors Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History

More information

Male Factor Infertility and Health. Karen Baker, MD Associate Professor Duke University, Division of Urology

Male Factor Infertility and Health. Karen Baker, MD Associate Professor Duke University, Division of Urology Male Factor Infertility and Health Karen Baker, MD Associate Professor Duke University, Division of Urology Fertility and Cancer Heart disease Metabolic syndrome Diabetes Early death Goals: Review literature

More information

PHD STUDENTSHIP PROJECT PROPOSAL

PHD STUDENTSHIP PROJECT PROPOSAL The Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL PROJECT DETAILS Project Title: Short Project Title: SUPERVISORY TEAM Primary Supervisor(s): Understanding therapeutic responses in BRCA

More information

Understanding Biological Activity to Inform Drug Development

Understanding Biological Activity to Inform Drug Development National Cancer Policy Forum Understanding Biological Activity to Inform Drug Development December 12, 2016 Wolfgang Weber Molecular Imaging and Therapy Service Department of Radiology RECIST Response

More information

Spring 2015 Module 2 System Engineering and Protein Founda<ons

Spring 2015 Module 2 System Engineering and Protein Founda<ons 20.109 Spring 2015 Module 2 System Engineering and Protein Founda

More information

Tumour growth environment modulates Chk1 signalling pathways and sensitivity to Chk1 inhibition

Tumour growth environment modulates Chk1 signalling pathways and sensitivity to Chk1 inhibition Tumour growth environment modulates Chk1 signalling pathways and sensitivity to Chk1 inhibition Andrew J Massey Supplementary Information Supplementary Figure S1. Related to Fig. 1. (a) HT29 or U2OS cells

More information

RESISTANCE RELATIONSHIPS BETWEEN PLATINUM AND PARP-INHIBITORS IN OVARIAN CANCER.

RESISTANCE RELATIONSHIPS BETWEEN PLATINUM AND PARP-INHIBITORS IN OVARIAN CANCER. RESISTANCE RELATIONSHIPS BETWEEN PLATINUM AND PARP-INHIBITORS IN OVARIAN CANCER. Britta Stordal 1, Yidong Chen 2, Angela Farrelly 3, Danielle Gallagher 3, Steven Busschots 1, Mattia Cremona 3, Mark Carey

More information

Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction

Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology

More information

Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 11-16-2017 Computational Investigation of Homologous Recombination DNA Repair

More information

609G: Concepts of Cancer Genetics and Treatments (3 credits)

609G: Concepts of Cancer Genetics and Treatments (3 credits) Master of Chemical and Life Sciences Program College of Computer, Mathematical, and Natural Sciences 609G: Concepts of Cancer Genetics and Treatments (3 credits) Text books: Principles of Cancer Genetics,

More information

Hereditary Breast and Ovarian Cancer: BRCA1 Failure and the Effectiveness of PARP Inhibitors. Vanessa Miraj Stuyvesant High School May 20,2013

Hereditary Breast and Ovarian Cancer: BRCA1 Failure and the Effectiveness of PARP Inhibitors. Vanessa Miraj Stuyvesant High School May 20,2013 + Hereditary Breast and Ovarian Cancer: BRCA1 Failure and the Effectiveness of PARP Inhibitors Vanessa Miraj Stuyvesant High School May 20,2013 + Physiology q 3-10% of breast or ovarian cancers are considered

More information

5/25/2015. Replication fork. Replication fork. Replication fork. Replication fork

5/25/2015. Replication fork. Replication fork. Replication fork. Replication fork Mutations Chapter 5 Cellular Functions Lecture 3: and Cell Division Most DNA mutations alter the protein product May Make it function better (rarely) Change its function Reduce its function Make it non-functional

More information

Radiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica

Radiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica Radiobiology of fractionated treatments: the classical approach and the 4 Rs Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica Radiobiology It is fundamental in radiation oncology Radiobiology

More information

Breast Cancer Statistics

Breast Cancer Statistics 1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty

More information

Precision Therapeutics For Hard-To-Treat Cancers

Precision Therapeutics For Hard-To-Treat Cancers Precision Therapeutics For Hard-To-Treat Cancers George O. Elston, CEO Life Sciences Summit November 2, 2017 1 About Us Precision therapeutics addressing significant unmet medical needs in hard-to-treat

More information

WO 2017/ Al. cc cc. 27 April 2017 ( ) P O P C T

WO 2017/ Al. cc cc. 27 April 2017 ( ) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International

More information

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California

More information

DNA Repair and Resistance to Cancer Therapy

DNA Repair and Resistance to Cancer Therapy Chapter 18 DNA Repair and Resistance to Cancer Therapy António S. Rodrigues, Bruno Costa Gomes, Célia Martins, Marta Gromicho, Nuno G. Oliveira, Patrícia S. Guerreiro and José Rueff Additional information

More information

Objectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice

Objectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice Heather Hampel, MS, CGC Associate Director, Division of Human Genetics Professor, Department of

More information

Cancer statistics (US)

Cancer statistics (US) Disclosure I have no financial relationships to disclose Biology and Introduction to the Genetics of Cancer Vickie Matthias Hagen, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line

More information

Hereditary Gynecologic Cancer 15 Years of Progress

Hereditary Gynecologic Cancer 15 Years of Progress Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial

More information

Immune therapy for women with recurrent ovarian cancer

Immune therapy for women with recurrent ovarian cancer Immune therapy for women with recurrent ovarian cancer Sarah Adams, MD Associate Professor, Division of Gynecologic Oncology University of New Mexico Comprehensive Cancer Center The problem: overall survival

More information

Genetic Panel Testing and Implications for Cancer Care

Genetic Panel Testing and Implications for Cancer Care Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016

More information